Accelerate Diagnostics (NDAQ:AXDX) Change of Rating
This rating downgrade is probably noticed by equity traders, as NDAQ:AXDX is now trading -4.83% lower at $28.55 as of 8:11 AM New York time. Accelerate Diagnostics shares have [From2] 0% over the last 200 days, while the S&P500 has surged 6.00% over the same time.
Birchview Capital Lp had the largest stake with ownership of 2.18 million shares as of q2 2015 for 34.62% of the equity exposure. Selkirk Management Llc is another very bullish institutional investor who is possessing 291,400 shares of Accelerate Diagnostics or 4.88% of their equity exposure. Further, Newtyn Management Llc have 3.83% of their equity exposure invested in the company for 600,000 shares. The New York-based fund Miura Global Management Llc revealed it had bought a stake worth about 1.19% of the institutional investor’s stock portfolio in Accelerate Diagnostics. The New York-based fund Cannell Peter B & Co Inc is also positive about the stock, possessing 400,000 shares or 1.04% of their equity exposure.
Accelerate Diagnostics (NDAQ:AXDX) Profile
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results.
Accelerate Diagnostics (NDAQ:AXDX) traded down -4.83% on 13 December, hitting $28.55. A total of 456,054 shares of the company’s stock traded hands. This is down from average of 709,514 shares. Accelerate Diagnostics has a 52 week low of $16.75 and a 52 week high of $30.45. The company has a market cap of $1.58 billion and a P/E ratio of 0.
Get the latest Accelerate Diagnostics (NDAQ:AXDX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Accelerate Diagnostics (NDAQ:AXDX) was Lowered by Analysts at BTIG Research to a Neutral Rating appeared first on Octafinance.